Skip to main content

Table 2 Comparison of comorbidity data between mild and severe NAFLD cohorts

From: Differential DNA methylation of genes involved in fibrosis progression in non-alcoholic fatty liver disease and alcoholic liver disease

 

NAFLD (mild fibrosis) F0 to F2 ( n = 8)

NAFLD (severe fibrosis) F3 to F4 ( n = 9)

Statistical significance

Hypertension (N, %)

5 (62.5%)

4 (44%)

ns

Any hypertensive medication (N, %)

5 (62.5%)

6 (66%)

ns

T2DM (N, %)

8 (100%)

8 (100%)

ns

Insulin treated (N, %)

3 (37.5%)

3 (33.3%)

ns

Oral medication treated (N, %)

3 (37.5%)

7 (77.7%)

ns

Diet treated (N, %)

2 (25%)

1 (11.1%)

ns

Cardiovascular disease (N, %)

2 (25%)

2 (22.2%)

ns

Dyslipidemia treated with lipid lowering agents (N, %)

4 (50%)

6 (66.6%)

ns

1 Med (N, %)

3 (37.5%)

6 (66.6%)

ns

>2 Meds (N, %)

1 (12.5%)

0 (0%)

ns